Pro PG receives S19A approval for - Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen

Historical supply notice: This article relates to a previous medicine shortage or regulatory approval. Availability and regulatory status may have changed. Healthcare professionals should contact Pro Pharmaceuticals Group to confirm the current supply position.

For current Australian shortage and supply information, see medicine shortages in Australia.

Dear Healthcare Professional,

OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324 - shortage and alternative supply arrangement

Pro Pharmaceuticals Group (ProPG) advises that due to a shortage of Australian registered OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324.

ProPG has arranged for an alternative product Ozempic 0.25mg & 0.5mg solution for injection in pre-filled pen (USA) . The S19A product is registered and marketed in the USA and the supply is authorized under an exemption granted by the TGA under Section 19A of the Therapeutic Goods Act, 1989 until 30th September 2022.